Pfizer said on Monday that its COVID vaccine works for children aged 5 to 11 – and that it will seek US clearance for this age group in the very near future – which is a key step towards the start of vaccinations for young people.
The vaccine manufactured by Pfizer and its German partner BioNTech is already available for ages 12 and over; However, with the return of children to school and the highly contagious delta variant causing a huge increase in pediatric infections, a large number of parents are eagerly awaiting vaccinations for their young children. For school-aged children, Pfizer tested a lower dose, equivalent to one-third of the amount in each injection currently given. After their second dose, children aged five to eleven developed levels of anti-coronavirus antibodies as strong as adolescents and young adults
FDA chief Dr Peter Marks says that once Pfizer reports the results of the study, his agency will assess the data “hopefully in a few weeks” – to decide whether the injections are safe enough and effective for young children.
A second-largest US vaccine maker, Moderna is also studying its vaccines in school-aged children. Pfizer and Moderna are also studying at even younger ages, up to the age of six months. The results are expected later this year.
(WHNT News 19 Huntsville / www.whnt.com)